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Abstract
Rheumatoid arthritis (RA) is the most common form of inﬂammatory arthritis that affects the adult population. Early
diagnosis and treatment are the cornerstones to prevent joint damage and avoid long-term costs and disability. This article
reviews the limitations of the currently available tools for the evaluation of patients with early arthritis, including clinical
assessment, serologic markers and imaging modalities. It also discusses gene expression analysis, a newer and potentially
promising approach to the early diagnosis of RA.
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Introduction
Rheumatoid arthritis (RA) is the most common
inﬂammatory arthritis, affecting 0.5–1% of the
population. The identiﬁcation of the early stages of
the disease is challenging, as the pathogenesis of RA
remains unknown despite extensive research done in
the last three decades. To date, there are no speciﬁc
diagnostic criteria for early RA, hence the diagnosis
relies on the 1988 American College of Rheumatology
classiﬁcation criteria for RA (Arnett et al. 1988) and
the duration of the arthritic symptoms. These criteria
have two caveats: ﬁrst, they were created to bring
uniformity to the subjects studied in clinical research,
rather than for diagnostic purposes. Second, they were
developed based on the characteristics of patients with
long-standing disease, making them insensitive to
identify patients with early RA.
Importance of the problem
RA is not only a prevalent disease but it is also very
costly. It results in an economic burden of $20
billion/year in the US alone, from both the direct and
indirect costs. Moreover, most of the costs come from
joint damage, which occurs early in the disease and
evolves in a linear and progressive fashion (Fuchs et al.
1989). Around 40% of patients with RA will
develop bone erosions as early as 6 months and up to
70% in the ﬁrst 2 years of onset of symptoms
(Hulsmans et al. 2000).
However, early treatment can prevent joint damage
andpreserveworkcapacity(Lardetal.2001;Puolakka
et al. 2005) making the need for early identiﬁcation of
patients imperative, and the institution of early
aggressive treatment to suppress inﬂammation and
ultimately prevent joint destruction crucial.
So, why not to treat all patients with early polyarthritis
as rheumatoid arthritis?
Although this seems an attractive approach, there are
several issues inherent to the disease itself and its
treatment. The ﬁrst problem is that patients present-
ing with early synovitis are very heterogeneous. In the
study of subjects with symptoms for less than 6
months, different cohorts have shown that at the time
of the ﬁrst evaluation, the prevalence of RA is very
broad (25–60%) (Hitchon et al. 2005), and 40–75%
of patients met criteria for other diagnoses such as
psoriatic arthritis, spondyloarthropathies or undiffer-
entiated polyarthritis (UP). To add to the confusion, a
subset (15–50%) of patients initially classiﬁed as UP
will develop a classiﬁable disease like RA during
follow up.
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and treatment of UPare different from those of RA. In
general,UPhasamorebenigncoursewithhigher rates
of spontaneous remission and with only a minority of
patients having persistent disease and erosions during
followup(Moreletal.2000).This becomes important
when one realizes that the treatment of RA is far from
being benign and risk-free.
Available tools for the identiﬁcation of patients
with early RA
As clinicianswerely on three tools to diagnose patients
as having RA:
1. Clinical criteria.
2. Serologic markers.
3. Radiographic evidence of joint damage.
As previously discussed, clinical criteria remain an
insensitivewaytoapproachpatientswith earlyarthritis
due to the heterogeneity of the early arthritis
population, the lack of validated criteria that are
speciﬁc for early RA, and the fact that many patients
canevolveintoadeﬁneddiagnosticcategoryover time.
Itisalsoremarkablethatdespiteextensiveresearchwe
lack a biologic marker to be used as a screening tool in
the clinical setting. For many years, rheumatoid factor
(RF)hasbeenusedasanaidinthediagnosisofRA,and
itisoneoftheitemsintheACRclassiﬁcationcriteriafor
RA. Unfortunately, sensitivity and speciﬁcity of RF for
RA,eveninestablishedformsofthedisease,areonly80
and 85%, respectively. A second marker that has
become widely used in the last few years is antibodies
against cyclic citrullinated peptide (CCP). Despite the
high speciﬁcity of CCP antibodies for RA (96%), they
have low sensitivity (60–80%) and therefore are not
useful as a screening tool (Avouac et al. 2006).
Imaging modalities such as MRI and ultrasound of
hands and feet have attracted considerable interest as
possible aids in the identiﬁcation of patients with early
RA. Severalpublications havedemonstrated thatthese
modalities are more useful than conventional X-ray in
detecting erosions and synovitis (Hoving et al. 2004).
However, there are several concerns with their use
including the reproducibility of the ﬁndings, as they
can be operator/reader dependent, their cost, and the
time they demand. Finally, the precise long-term
implications of MRI abnormalities and their role in
treatment decisions are still not clear.
It is apparent that the need for additional tools to aid
in the early diagnosis of RA becomes crucial in order
to institute prompt treatment to prevent disability.
Future directions
Gene expression analysis has emerged as a potentially
useful tool in the research and approach to patients
with complex diseases, such as autoimmune con-
ditions. This approach is a method of analysing the
differential expression of thousands of species of
messenger RNA (mRNA) simultaneously in two
different samples. This novel technique permits the
comparison of the complex changes that occur in cells
andtissuesoftheimmunesysteminhealthanddisease.
Using this technique, accurate classiﬁcation of
patientswithconnectivetissuediseasehasbeenpossible
even when the clinical scenario is not known. For
example, utilization of gene array analysis of synovial
specimens has shown to be useful in delineating
differences between patients with established RA and
those with osteoarthritis (Devauchelle et al. 2004).
Regrettably,synovialsamplesarenotreadilyavailablein
clinical practice as their procurement involves an
invasive procedure. Furthermore, in the earliest RA
patients, synovial tissue is not readily available.
More recently, Olsen et al. (2004) attempted to
circumvent the need for using synovial tissue for gene
expression analysis by using peripheral blood mono-
nuclear cells. They have shown that a speciﬁc
signature on gene array in peripheral blood mono-
nuclear cells is present in patients with early RA. This
signature differentiates them from patients with
established RA and healthy controls, suggesting that
it may be possible to proﬁle patientswith early arthritis
who will meet classiﬁcation criteria for RA in follow
up, and who may beneﬁt from close and perhaps more
aggressive treatment. This approach has the potential
of providing an easy, readily accessible tool to
clinicians in both the primary care setting and in
rheumatology clinics to evaluate these patients, with
the advantage of not requiring invasive procedures,
expensive equipment or trained readers.
Despite the initial enthusiasm generated by these
ﬁndings, larger studies are needed to validate and
standardize these data, and to develop a clinically
useful tool to diagnose patients with early RA.
Conclusion
Early identiﬁcation of patients with RA is crucial to
prevent joint damage and disability. Despite great
advance in our understanding of the disease, we still
rely on less than ideal tools such as the combination of
clinical ﬁndings, serologic markers and imaging tech-
niques to identify such patients. New horizons to
approach and diagnose patients with early arthritis are
opening with the use of newer techniques such as gene
expression analysis. However, we should be cautious
untillargerandwell-standardizedstudiesareperformed.
References
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS,
et al. 1988. The American Rheumatism Association 1987
C. Orozco & N. J. Olsen 296revised criteria for the classiﬁcation of rheumatoid arthritis.
Arthritis Rheum 31:315–324.
Avouac J, Gossec L, Dougados M. 2006. Diagnostic and predictive
value of anti-CCP (cyclic citrullinated protein) antibodies in
rheumatoid arthritis: A systematic literature review. Ann Rheum
Dis, 65: 845–851.
Devauchelle V, Marion S, Cagnard N, Mistou S, et al. 2004. DNA
microarray allows molecular proﬁling of rheumatoid arthritis
and identiﬁcation of pathophysiological targets. Genes Immun
5:597–608.
FuchsHA,KayeJJ,CallahanLF,NanceEP,PincusT.1989.Evidence
of signiﬁcant radiographic damage in rheumatoid arthritis within
the ﬁrst 2 years of disease. J Rheumatol 16:585–591.
Hitchon CA, Peschken CA, Shaikh S, El-Gabalawy HS. 2005. Early
undifferentiated arthritis. Rheum Dis Clin North Am 31(4):
605–626.
Hoving JL, Buchbinder R, Hall S, Lawler G, et al. 2004. A
comparison of magnetic resonance imaging, sonography, and
radiography of the hand in patients with early rheumatoid
arthritis. J Rheumatol 31:663–675.
Hulsmans HM, Jacobs JW, vander Heijde DM, vanAlbada-Kuipers
GA, Schenk Y, Bijlsma JW. 2000. The course of radiologic
damage during the ﬁrst six years of rheumatoid arthritis.
Arthritis Rheum 43:1927–1940.
Lard LR, Visser H, Speyer I, Vander Horst-Bruinsma IE, et al.
2001. Early versus delayed treatment in patients with
recent-onset rheumatoid arthritis: Comparison of two cohorts
who received different treatment strategies. Am J Med
111:446–451.
Morel J, Legouffe MC, Bozonat MC, Sany J, et al. 2000. Outcomes
in patients with incipient undifferentiated arthritis. Joint Bone
Spine 67(1):49–53.
Olsen NJ, Sokka T, Seehorn CL, Kraft B, et al. 2004. A gene
expression signature for recent onset rheumatoid arthritis in
peripheral blood mononuclear cells. Ann Rheum Dis 63:
1387–1392.
Puolakka K, Kautiainen H, Mo ¨tto ¨nen T, et al. 2005. Early
supression of disease activity is essential for maintenance of work
capacity in patients with recent onset rhematoid arthritis.
Arthritis Rheum 52:36–41.
Identiﬁcation of patients with early rheumatoid arthritis 297